Emerphed (Ephedrine Sulfate) Patent Expiration, LOE Window & CMS Spending

Emerphed (Ephedrine Sulfate) by Nexus: FDA Orange Book LOE 2040-05-16, 0 AB generics, $3.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNexus
FDA Application & PathwayN213407 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2040-05-16
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$3.0M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$3.0M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel